A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Preclinical data suggest that a “prime-boost” vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a clinical setting. CMB305 is a prime-boost vaccine design...

Descripción completa

Detalles Bibliográficos
Autores principales: Somaiah, Neeta, Chawla, Sant P., Block, Matthew S., Morris, John C., Do, Khanh, Kim, Joseph W., Druta, Mihaela, Sankhala, Kamalesh K., Hwu, Patrick, Jones, Robin L., Gnjatic, Sacha, Kim-Schulze, Seunghee, Tuballes, Kevin, Yishak, Mahlet, Lu, Hailing, Yakovich, Adam, Ter Meulen, Jan, Chen, Michael, Kenney, Richard T., Bohac, Chet, Pollack, Seth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714520/
https://www.ncbi.nlm.nih.gov/pubmed/33312760
http://dx.doi.org/10.1080/2162402X.2020.1847846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714520/
https://www.ncbi.nlm.nih.gov/pubmed/33312760
http://dx.doi.org/10.1080/2162402X.2020.1847846

Ejemplares similares